EUVIMEDEUVIMED entdecken
Crossref

Disproportionality analysis of hematologic adverse events associated with trastuzumab deruxtecan using the Japanese pharmacovigilance database

Yuko Kanbayashi, Risa Morioka, Koichi Takayama, Keiko Hosohata

Clinical and Translational Oncology · 2026

DOI: 10.1007/s12094-026-04239-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Oncology, 2026. Verfasst von Yuko Kanbayashi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Evaluation for Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Himeji Dokkyo University, 7-2-1 Kami-Ohno, Himeji, Hyogo, 670…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Immunological, Hematologic Diseases, Pharmacovigilance, Trastuzumab. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To evaluate the disproportionality, time to onset, reporting frequency, and outcomes of hematologic AEs associated with trastuzumab deruxtecan (T-DXd) using data from the Japanese Adverse Drug Event Report database (JADER). METHODS: We analyzed data for the period from April 2004 to December 2024. Data on hematologic AEs were extracted, and the disproportionality of T-DXd-associated AEs was assessed by calculating reporting odds ratios. RESULTS: Among the 3,221,393 reports analyzed, 1561 were associated with T-DXd, including 433 hematologic AEs. Signals were detected for six AEs, including febrile neutropenia, anaemia, neutrophil count decreased, neutropenia, platelet count decreased, and myelosuppression. All had fatal cases, with particularly high fatality rates observed for febrile neutropenia and platelet count decreased. A histogram of median times to onset showed that febrile neutropenia and platelet count decreased typically occurred within 8 to 10.5 days after administration. Weibull distribution analysis indicated that febrile neutropenia showed an early-onset tendency (early failure type), whereas platelet count decreased occurred in a dose-dependent manner (wear-out failure type). CONCLUSIONS: Some hematologic AEs associated with T-DXd can be fatal and may occur not only early in treatment but also later in the course. Continuous monitoring is essential for their timely detection and appropriate management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Agents, ImmunologicalHematologic DiseasesPharmacovigilanceTrastuzumabFemaleHumansMaleAdverse Drug Reaction Reporting SystemsDatabases, FactualJapanPlatelet Count

Stichwörter der Autor:innen

Hematologic adverse eventJapanese Adverse Drug Event Report databaseOutcomeTime to onsetTrastuzumab deruxtecan

Substanzen

Antineoplastic Agents, ImmunologicalTrastuzumab

Autor:innen und Institutionen

  • Department of Evaluation for Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Himeji Dokkyo University, 7-2-1 Kami-Ohno, Himeji, Hyogo, 670-8524, Japan. ykokanba@gm.himeji-du.ac.jp.
  • Department of Drug Evaluation and Informatics, Faculty of Pharmaceutical Sciences, Himeji Dokkyo University, 7-2-1 Kami-Ohno, Himeji, Hyogo, 670-8524, Japan.
  • Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Zitieren

APA

Kanbayashi, Y., Morioka, R., Takayama, K., & Hosohata, K. (2026). Disproportionality analysis of hematologic adverse events associated with trastuzumab deruxtecan using the Japanese pharmacovigilance database. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-026-04239-2

Vancouver

Kanbayashi Y, Morioka R, Takayama K, Hosohata K. Disproportionality analysis of hematologic adverse events associated with trastuzumab deruxtecan using the Japanese pharmacovigilance database. Clinical and Translational Oncology. 2026. doi:10.1007/s12094-026-04239-2

BibTeX
@article{Kanbayashi2026,
  author = {Kanbayashi, Yuko and Morioka, Risa and Takayama, Koichi and Hosohata, Keiko},
  title = {Disproportionality analysis of hematologic adverse events associated with trastuzumab deruxtecan using the Japanese pharmacovigilance database},
  journal = {Clinical and Translational Oncology},
  year = {2026},
  doi = {10.1007/s12094-026-04239-2}
}
Kostenlos starten →